
Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 02, 2024, titled "Zydus receives tentative approval from USFDA for Enzalutamide Tablets, 40 mg and 80 mg".
Filed with NSE ·

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated October 02, 2024, titled "Zydus receives tentative approval from USFDA for Enzalutamide Tablets, 40 mg and 80 mg".
6ix hasn’t read this filing yet.
Zydus Lifesciences Limited on 6ix
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences